China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE: 300294)
Health Care · Biotechnology · CN
CN¥14.88
-0.40% today · -40.0% 1Y
China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE: 300294) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.12B and employs 1,947 people.
Over the last twelve months the share price has lost 40.0%, trading between 13.64 and 25.64.
Tweenvest scores China Resources Boya Bio-pharmaceutical Group Co.,Ltd across four factors: quality 68/100, value 75/100, growth 25/100. Its strongest factor is value.
300294 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.12B
- Revenue (TTM)
- $249.51M
- P/E
- —
- EPS
- -0.12
- Dividend yield
- —
- Beta (5Y)
- 0.40
- 52-week high
- CN¥25.64
- 52-week low
- CN¥13.64
- Avg volume (3M)
- —
- Shares outstanding
- 504.25M
- Employees
- 1,947
- Next earnings
- —
About China Resources Boya Bio-pharmaceutical Group Co.,Ltd
Established in 1993 and headquartered in Fuzhou, China, China Resources Boya Bio-pharmaceutical Group Co., Ltd. (formerly Boya Bio-pharmaceutical Group Co., Ltd.) is a comprehensive pharmaceutical enterprise operating across China. The company is engaged in the research, development, production, and sale of a diverse portfolio, primarily focusing on blood products, diabetes medications, and various biochemical and chemical pharmaceuticals. Its extensive range of blood-derived products includes human fibrinogen, human albumin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, and freeze-dried intravenous human immunoglobulin. For diabetes management, the company offers metformin hydrochloride (both tablets and enteric-coated versions), pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Additionally, it produces specialized injections such as compound osteotide, oxytocin, and heparin sodium, which are utilized across numerous medical fields, including general medicine, hepatitis treatment, gynecology, and immunomodulatory applications.
- ISIN
- CNE100001FF1
- Founded
- 1993
- Listed since
- Mar 8, 2012
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nanjing Leads Biolabs Co., Ltd.SEHK: 9887 | $1.13B | HK$45.56 | -9.69% |
| L&C BIO Co.,LTDKOSDAQ: A290650 | $1.13B | ₩56,400.00 | +5.03% |
| Janux Therapeutics, Inc.NasdaqGM: JANX | $1.12B | $18.17 | -1.20% |
| HOB Biotech Group Corp.,LtdSHSE: 688656 | $1.12B | CN¥120.00 | -8.90% |
| Oncolys BioPharma Inc.TSE: 4588 | $1.11B | ¥5,970.00 | -0.17% |
| Changchun BCHT Biotechnology Co.SHSE: 688276 | $1.10B | CN¥17.79 | -0.89% |
| GC Biopharma Corp.KOSE: A006280 | $1.10B | ₩129,400.00 | +2.86% |
| Chengdu Kanghua Biological Products Co., Ltd.SZSE: 300841 | $1.07B | CN¥55.26 | -1.95% |
Figures last refreshed Oct 11, 2026.